Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

April 30, 2020

Study Completion Date

April 30, 2020

Conditions
GlioblastomaRecurrent GlioblastomaBrain Tumor
Interventions
DRUG

Tesevatinib

Trial Locations (11)

10032

Columbia University, Herbert Irving Comprehensive Cancer Center, New York

44195

Cleveland Clinic, Cleveland

48202

Henry Ford Hospital, Detroit

77030

UT MD Anderson Cancer Center, Houston

80045

University of Colorado Cancer Center, Aurora

84112

Huntsman Cancer Institute, Salt Lake City

85718

Center for Neurosciences, Tucson

91010

City of Hope, Duarte

94143

University of California, San Francisco (UCSF), San Francisco

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

All Listed Sponsors
lead

Kadmon Corporation, LLC

INDUSTRY

NCT02844439 - Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma | Biotech Hunter | Biotech Hunter